Table 2.
Logistic regression models for any local treatment complication*
| Variable | MarketScan cohort* |
SEER-Medicare cohort |
||
|---|---|---|---|---|
| RR (95% CI) | P† | RR (95% CI) | P† | |
| Local therapy | ||||
| Lump+WBI | 1 (Ref) | 1 (Ref) | ||
| Lump+Brachy | 1.47 (1.40 to 1.53) | <.001 | 1.36 (1.31 to 1.41) | <.001 |
| Lump alone | 1.10 (1.04 to 1.16) | .001 | 0.87 (0.83 to 0.90) | <.001 |
| Mast alone | 0.88 (0.85 to 0.91) | <.001 | 0.98 (0.96 to 1.00 | .08 |
| Mast+Recon | 1.87 (1.82 to 1.91) | <.001 | 1.75 (1.69 to 1.82) | <.001 |
| Age, y | ||||
| <40 | 1 (Ref) | |||
| 40–49 | 1.04 (0.99 to 1.10) | .14 | ||
| 50–59 | 1.05 (1.00 to 1.11) | .06 | ||
| 60–64 | 1.08 (1.01 to 1.14) | .01 | ||
| 66–69 | 1 (Ref) | |||
| 70–74 | 1.00 (0.97 to 1.03) | 1.00 | ||
| 75–79 | 0.97 (0.94 to 1.00) | .05 | ||
| 80–84 | 0.94 (0.91 to 0.97) | <.001 | ||
| 85+ | 0.94 (0.90 to 0.98) | .003 | ||
| Race | ||||
| White | 1 (Ref) | |||
| Black | 0.95 (0.90 to 0.99) | .02 | ||
| Other/Unknown | 0.88 (0.84 to 0.93) | <.001 | ||
| Comorbidity | ||||
| 0 | 1 (Ref) | 1 (Ref) | ||
| 1 | 1.24 (1.19 to 1.29) | <.001 | 1.10 (1.08 to 1.13) | <.001 |
| 2 or higher | 1.37 (1.26 to 1.48) | <.001 | 1.26 (1.22 to 1.29) | <.001 |
| Chemotherapy | ||||
| None | 1 (Ref) | 1 (Ref) | ||
| Without trastuzumab | 1.14 (1.11 to 1.18) | <.001 | 1.05 (1.01 to 1.08) | .01 |
| With trastuzumab | 1.20 (1.14 to 1.27) | <.001 | 1.03 (0.97 to 1.10) | .32 |
| Axillary surgery | ||||
| No | 1 (Ref) | |||
| Yes | 1.14 (1.09 to 1.19) | <.001 | ||
| Node positive | ||||
| No | 1 (Ref) | |||
| Yes | 1.11 (1.08 to 1.15) | <.001 | ||
*
No patients were excluded from either model. Brachy = brachytherapy; Lump = lumpectomy; Mast = mastectomy; Recon = reconstruction; SEER = Surveillance, Epidemiology, and End Results; WBI = whole breast irradiation.
†
All P values were two-sided and calculated in the logistic regression models.